More specifically, STAG2 mutation has been identified in a significant number of solid tumor types, including bladder, endometrial, stomach, and colorectal cancers.[9] In accordance with genomic datasets of tumor patients (cBioPortal), ≈41% of STAG2 mutants are truncating mutations that are recognized as putative pathogenic mutations.[41] SL provides a conceptual framework for developing targets that are traditionally undruggable in malignancies. Here, STAG2 is linked to neoplasm.